Royalty Pharma Corp (RPRX): Forecast Levels Chart

Symbol and logo of brand Royalty Pharma Corp (RPRX)

Serving as an assessment tool, the Royalty Pharma plc (RPRX) price chart allows for an analysis of the biopharmaceutical ecosystem's efficiency, where capital drives medical advancement and the indicator stands at 72.94. Royalty Pharma plc sponsors research centers and laboratories to conduct complex testing. Business stability is guaranteed by the ownership of patents for popular drugs, which eliminates production costs and ensures a high return on assets.

RPRX: Royalty Pharma PLC Consensus Target 07/04/2022 - 11/11/2026

Metric breakdowns and analytics for Royalty Pharma Corp (RPRX)

- share price and consensus valuation forecast:
Price Performance Chart royaltypharma.com|RPRX - Price Target Chart
- stock exchange capitalization data:
Market Valuation Royalty Pharma Corp|RPRX - Total Company Value
- balance sheet net asset value indicators:
Accounting Value of a Share Royalty Pharma|RPRX - Company Net Assets|Capitalization to Book Value Ratio royaltypharma.com|RPRX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Royalty Pharma plc|RPRX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Royalty Pharma Investments|RPRX - Company Total Debt|Debt to Book Capitalization Ratio Royalty Pharma Corp|RPRX - Company Long-Term Debts|Short-Term Debt Royalty Pharma|Interim Coverage Ratio royaltypharma.com
- earnings and valuation multiples information:
RPRX - Net Income|Future Net Profit Royalty Pharma plc|RPRX - Price to Earnings Ratio|Future Price to Earnings Multiple Royalty Pharma PLC|RPRX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Royalty Pharma Corp|RPRX - Operating profit EBITDA|Net earnings per one share for the last twelve months Royalty Pharma|RPRX - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months royaltypharma.com|RPRX - Earnings per share growth in current year|Expected net earnings per share growth next year Royalty Pharma plc
Summary company analytics:royaltypharma.com RPRX
Core merchandise of royaltypharma.com

For an investor in Royalty Pharma plc (RPRX), this indicator serves as a gauge of market expectations regarding the fair value of assets generating stable cash flow from oncology drugs. The current consensus valuation level on GURU.Markets aggregates average expert forecasts, reflecting the balance of supply and demand, which allows for an assessment of the stock's overbought status against the cost of capital and future rights to new molecules.

Competing companies

TPL (texaspacific.com) - Fair Value Consensus|Price Target Chart Viper Energy VNOM|BSM (Black Stone Minerals LP) - Forecast Levels Chart|NOG - Price Target Chart|Fair Value Consensus DMLP (Dorchester Minerals Partnership)|SBR (Sabine Royalty Trust) - Consensus Target|Broker Consensus Forecast VTS|PBT (Permian Basin Royalty Trust REIT) - Analyst Consensus Forecast|TXO Partners LP (TXO) - Analyst Median Target|Price Target Chart Granite Ridge (GRNT)|xoma.com - Broker Consensus Forecast|San Juan Basin Royalty Trust Unit - Consensus Target|Streamex Corporation - Price Target Chart|Scully Royalty Limited - Analyst Consensus Forecast|Average Forecast Price MV Oil Trust, Inc.|Permianville Royalty Trust, Inc. (PVL) - Price Target Chart|VOC - Analyst Median Target|Consensus Target CRT|PRT (permrock.com) - Analyst Forecast Prices|Consensus Target RMCO (Royalty Management Holding Corporation)|CKX (ckxlands.com) - Fair Value Consensus|Price Target Chart Mesa Royalty Trust Inc. MTR|Fair Value Consensus BPT|PHX Minerals Inc. - Analyst Consensus Forecast|Average Forecast Price sitio.com